Dual/triple agonist research class (non-reta)

This comparison class groups metabolic peptides people discuss for quieter food noise, weight loss and liver-fat effects. It is not one compound called ECCN. Appetite relief, stomach symptoms and response differ between molecules; milligram amounts cannot be exchanged between agents.

A class map, not a blend recipe. These are engineered molecules, not mixtures with a universal ingredient ratio. Retatrutide has its own card. Novo's pipeline also names UBT251, a GLP-1, GIP and glucagon triple; that is formal context, not a user log. CagriSema combines amylin and GLP-1 agents. Weekly under-skin injections dominate modern discussion, while cotadutide's historical design used daily injections. Klein et al. — Cotadutide pharmacokinetics in renal impairment (Official context · Accessed 2026-09-30) · r/GLP1ResearchTalk — Mazdutide: Entry #22 of 100+ Peptides (Community guide · Accessed 2026-09-30) · Novo Nordisk Annual Report 2025 — Innovation and therapeutic focus (Official context · Accessed 2026-09-30)

One peptide, several receptor targets. Tirzepatide targets GLP-1 and GIP. Mazdutide, survodutide and pemvidutide target GLP-1 and glucagon. GLP-1 regulates appetite and glucose; glucagon interest centers on liver-fat metabolism and energy expenditure. Receptor balance differs between molecules. r/GLP1ResearchTalk — Mazdutide: Entry #22 of 100+ Peptides (Community guide · Accessed 2026-09-30) · DailyMed — ZEPBOUND prescribing information (Official context · Accessed 2026-09-30) · Altimmune — Pemvidutide development overview (Official context · Accessed 2026-09-30) · Boehringer Ingelheim — SYNCHRONIZE-1 announcement (Official context · Accessed 2026-09-30)

Source context — Klein et al. — Cotadutide pharmacokinetics in renal impairment: Small single-dose human bridging study with different renal-function groups. Not a community measurement or a class-wide duration value.

Source context — r/GLP1ResearchTalk — Mazdutide: Entry #22 of 100+ Peptides: User-created explainer, not a first-person log. Its weekly half-life wording is not a numeric PK result. Regulatory assertions and trial-arm grouping were not accepted as current facts.

Source context — Novo Nordisk Annual Report 2025 — Innovation and therapeutic focus: Developer's annual report used for molecule/combination identity only. No community dose, firsthand outcome or pipeline success inferred.

Source context — DailyMed — ZEPBOUND prescribing information: Approved tirzepatide product only; does not validate investigational products, community interval changes or multi-agonist combinations.

Source context — Altimmune — Pemvidutide development overview: Developer's commercially interested overview. Only identity and investigational nature used; efficacy and development forecasts are not independent confirmation.

Source context — Boehringer Ingelheim — SYNCHRONIZE-1 announcement: Sponsor communication. Receptor identity used only; topline effectiveness and claims of differentiated effects not adopted as community experience.

Less food preoccupation and easier maintenance. Tirzepatide users describe keeping weight steady without making eating difficult; others regain after reducing it. Physical fullness and fewer cravings can separate, so feeling full does not necessarily stop wanting food. r/TirzepatideRX — What maintenance actually looks like (Community discussion · Accessed 2026-09-30) · r/survodutide — Week of 4/29 thread (Community discussion · Accessed 2026-09-30)

A slow response remains part of the picture. A blinded survodutide participant reports about one pound lost monthly since February despite reduced hunger, then headaches, constipation and nausea-like symptoms. They believe they received medication; unknown allocation prevents calling this confirmed drug failure. r/survodutide — I'm not responding (Personal report · Accessed 2026-09-30)

Liver and body-composition hopes. Pemvidutide discussion includes hopes for liver improvement and less muscle loss. The inspected liver thread contains anticipation, including investor optimism, rather than a pemvidutide treatment log. A daily feeling of burning fat does not measure liver-fat change. r/FattyLiverNAFLD — Has anyone heard or tried pemvidutide? (Community opinion · Accessed 2026-09-30)

Source context — r/TirzepatideRX — What maintenance actually looks like: Unverified doses, formulations and weight trends. Different people supply the amount and split-dose success/failure accounts; no comparative trial or class recommendation.

Source context — r/survodutide — Week of 4/29 thread: Blinded trial accounts; assignments and identities unverified. Steps are trial-origin, not a community dose-finding study. Separate participants and endpoints must not be pooled.

Source context — r/survodutide — I'm not responding: Blinded allocation unknown; symptoms do not reveal assignment. Weight, diet and exercise are unverified self-reports; exact publication date not established.

Source context — r/FattyLiverNAFLD — Has anyone heard or tried pemvidutide?: Optimism and trial repetition, not pemvidutide first-person use. Commenter discloses buying Altimmune stock; reported liver-lab improvement concerns tirzepatide instead.

Survodutide: 1.2 mg and 2.4 mg weekly trial injections. Participant-reported titration steps retain trial origins and unconfirmed blinded allocation. Older forum charts copy trial ladders toward 3.6–6 mg weekly; these are not class-wide targets. r/survodutide — Week of 4/29 thread (Community discussion · Accessed 2026-09-30)

Mazdutide: 3 mg per week in one self-experiment. That poster also added HGH; product and route were unspecified. A different commenter mentions starting 4 mg after a month without stating frequency. Older community charts circulate 1.5–3 mg starts and 3, 6 or 9 mg weekly holds, borrowed from trial discussions rather than a verified class regimen. r/BodyHackGuide — HGH / Mazdutide Stack (Personal report · Accessed 2026-09-30) · r/Biohacking — Mazdutide (Community discussion · Accessed 2026-09-30)

Tirzepatide: separate maintenance accounts. One reports 2 mg every 7–10 days; another reports injected 7.5 mg about every 10 days. Formulation and injection depth are not specified. Neither amount is a daily total or transferable to another molecule. r/TirzepatideRX — What maintenance actually looks like (Community discussion · Accessed 2026-09-30)

Flatter exposure is a debated goal. Older notes describe splitting a weekly injection total roughly 3–4 days apart to reduce peaks or nausea. One reviewed tirzepatide account splits 10 mg total into two injections weekly, while another says splitting did not help. These reports neither establish improved safety nor validate split schedules for other duals. r/TirzepatideRX — What maintenance actually looks like (Community discussion · Accessed 2026-09-30)

Source context — r/survodutide — Week of 4/29 thread: Blinded trial accounts; assignments and identities unverified. Steps are trial-origin, not a community dose-finding study. Separate participants and endpoints must not be pooled.

Source context — r/BodyHackGuide — HGH / Mazdutide Stack: 3 mg/week report lacks route or product authentication. Added HGH, training, diet and alcohol change confound outcomes; subreddit promotes commercial guides. No mazdutide outcome measurement is supplied.

Source context — r/Biohacking — Mazdutide: Product, route and dosing frequency unspecified. Combination loss is not a mazdutide monotherapy result. Relative dates shown; exact post date not verified.

Source context — r/TirzepatideRX — What maintenance actually looks like: Unverified doses, formulations and weight trends. Different people supply the amount and split-dose success/failure accounts; no comparative trial or class recommendation.

Hours for symptoms; weeks for appetite change. One survodutide participant noticed an effect around two hours after injection; another noticed strong hunger suppression at injection nine. A mazdutide commenter describes first-week nausea and sleepiness. Different people and effects cannot define one class timeline. r/survodutide — Week of 4/29 thread (Community discussion · Accessed 2026-09-30) · r/Biohacking — Mazdutide (Community discussion · Accessed 2026-09-30)

Survodutide: two or three days versus all week. Separate participants describe those appetite windows; the all-week report also describes about six hours of nausea and lightheadedness. That is felt duration, not bodily half-life. r/survodutide — Week of 4/29 thread (Community discussion · Accessed 2026-09-30)

Tirzepatide: the strongest days can shift. Some describe early suppression on days 1–4, later on days 5–7. Another feels late-week hunger while cravings stay quiet. Appetite, food noise and side effects differ. r/tirzepatidecompound — 5 day half life (Community discussion · Accessed 2026-09-30)

No single class half-life. Tirzepatide discussion repeats about 5 days from clinical PK, not user-measured clearance. Replies challenge treating day five as sudden loss of effect. A mazdutide explainer supplies a weekly schedule, not a measured half-life. The inspected personal accounts establish no human clearance estimates for the other agents. r/tirzepatidecompound — 5 day half life (Community discussion · Accessed 2026-09-30) · r/GLP1ResearchTalk — Mazdutide: Entry #22 of 100+ Peptides (Community guide · Accessed 2026-09-30)

Clinical clocks differ. Tirzepatide's label gives about 5–6 days. After 100 micrograms subcutaneous, cotadutide mean terminal half-lives were 8.5–10.8 hours across renal-function groups. Altimmune's pemvidutide table lists 110 hours at 1.8 mg subcutaneous. These are formal values, not a class range or measurements from personal reports. DailyMed — ZEPBOUND prescribing information (Official context · Accessed 2026-09-30) · Klein et al. — Cotadutide pharmacokinetics in renal impairment (Official context · Accessed 2026-09-30) · Klein et al. / Altimmune — Pemvidutide Phase 1 presentation (Official context · Accessed 2026-09-30)

Source context — r/survodutide — Week of 4/29 thread: Blinded trial accounts; assignments and identities unverified. Steps are trial-origin, not a community dose-finding study. Separate participants and endpoints must not be pooled.

Source context — r/Biohacking — Mazdutide: Product, route and dosing frequency unspecified. Combination loss is not a mazdutide monotherapy result. Relative dates shown; exact post date not verified.

Source context — r/tirzepatidecompound — 5 day half life: Five-day number is repeated clinical PK, not human clearance measured by commenters. Calculator fractions and dosing recommendations are not adopted. Formulations vary.

Source context — r/GLP1ResearchTalk — Mazdutide: Entry #22 of 100+ Peptides: User-created explainer, not a first-person log. Its weekly half-life wording is not a numeric PK result. Regulatory assertions and trial-arm grouping were not accepted as current facts.

Source context — DailyMed — ZEPBOUND prescribing information: Approved tirzepatide product only; does not validate investigational products, community interval changes or multi-agonist combinations.

Source context — Klein et al. — Cotadutide pharmacokinetics in renal impairment: Small single-dose human bridging study with different renal-function groups. Not a community measurement or a class-wide duration value.

Source context — Klein et al. / Altimmune — Pemvidutide Phase 1 presentation: Sponsor presentation, small Phase 1 study; context-specific value. The old 144-hour assertion was not corroborated. Does not provide a community half-life or personal onset time.

Ongoing maintenance, not a universal short cycle. Tirzepatide accounts describe months of maintenance, with longer intervals, lower amounts or continued weekly use. An unsuccessful reduction also appears. These reports do not establish an on/off cycle for every dual. r/TirzepatideRX — What maintenance actually looks like (Community discussion · Accessed 2026-09-30)

Less food preoccupation and easier maintenance. Tirzepatide users describe keeping weight steady without making eating difficult; others regain after reducing it. Physical fullness and fewer cravings can separate, so feeling full does not necessarily stop wanting food. r/TirzepatideRX — What maintenance actually looks like (Community discussion · Accessed 2026-09-30) · r/survodutide — Week of 4/29 thread (Community discussion · Accessed 2026-09-30)

Break and restart lore varies. Preserved discussion includes GI resets, travel, cost, supply interruptions, rebound and lower-step restarts after multi-week gaps. No validated class restart amount or on/off calendar follows.

Source context — r/TirzepatideRX — What maintenance actually looks like: Unverified doses, formulations and weight trends. Different people supply the amount and split-dose success/failure accounts; no comparative trial or class recommendation.

Source context — r/survodutide — Week of 4/29 thread: Blinded trial accounts; assignments and identities unverified. Steps are trial-origin, not a community dose-finding study. Separate participants and endpoints must not be pooled.

Switching and stacking obscure attribution. One poster credits weight loss to 3.6 mg survodutide plus 6 mg tirzepatide, frequency unspecified, nicknamed ghetto reta. That is neither an engineered triple nor a proven ratio. Other logs mix HGH, training and dietary changes; individual contributions cannot be isolated. r/Biohacking — Mazdutide (Community discussion · Accessed 2026-09-30) · r/BodyHackGuide — HGH / Mazdutide Stack (Personal report · Accessed 2026-09-30)

Mazdutide: 3 mg per week in one self-experiment. That poster also added HGH; product and route were unspecified. A different commenter mentions starting 4 mg after a month without stating frequency. Older community charts circulate 1.5–3 mg starts and 3, 6 or 9 mg weekly holds, borrowed from trial discussions rather than a verified class regimen. r/BodyHackGuide — HGH / Mazdutide Stack (Personal report · Accessed 2026-09-30) · r/Biohacking — Mazdutide (Community discussion · Accessed 2026-09-30)

Repulsive-Back-7538 opening body and Left-Championship482 response; extracted lines 21–28 and 77–81. r/BodyHackGuide — HGH / Mazdutide Stack (Personal report · Accessed 2026-09-30)

A lower scale number can include muscle loss. Community notes emphasize protein, lifting, sleep and movement, plus smaller meals, slower eating, fiber and fluids for tolerability. These habits guarantee neither lean-mass preservation nor relief from serious side effects.

Lifestyle co-exposures: Posters credit protein intake, resistance training, sleep and daily movement alongside medication for body-composition changes. The record does not establish near-universal agreement or isolate each contribution. [community]

Sparse adjuncts: Occasional lipid agents, sleep aids, or recovery peptides appear in n=1 logs with weak attribution to the multi-agonist’s effect. [anecdote]

PED-forum pairings: Some bodybuilding contexts pair multi-agonists with AAS/TRT for recomp — confounded, not clinical practice, and not a dosing standard. [anecdote]

Source context — r/Biohacking — Mazdutide: Product, route and dosing frequency unspecified. Combination loss is not a mazdutide monotherapy result. Relative dates shown; exact post date not verified.

Source context — r/BodyHackGuide — HGH / Mazdutide Stack: 3 mg/week report lacks route or product authentication. Added HGH, training, diet and alcohol change confound outcomes; subreddit promotes commercial guides. No mazdutide outcome measurement is supplied.

Side effects do not prove it is working. Survodutide accounts include vomiting after escalation, reflux without weight loss, and no side effects. The community record includes diarrhea shifting to constipation, fatigue and low intake. Severe persistent abdominal pain or inability to retain fluids warrants medical assessment. r/survodutide — Week of 4/29 thread (Community discussion · Accessed 2026-09-30) · DailyMed — ZEPBOUND prescribing information (Official context · Accessed 2026-09-30)

Receptor overlap and product identity matter. Vial labels do not verify contents. Tirzepatide's label discourages other GLP-1 agonists alongside it and addresses pancreatitis, gallbladder disease, dehydration, pregnancy, MTC/MEN2 contraindications and hypoglycemia with insulin or sulfonylureas. These are named-product cautions, not identical labels for all duals. DailyMed — ZEPBOUND prescribing information (Official context · Accessed 2026-09-30)

A lower scale number can include muscle loss. Community notes emphasize protein, lifting, sleep and movement, plus smaller meals, slower eating, fiber and fluids for tolerability. These habits guarantee neither lean-mass preservation nor relief from serious side effects.

Source context — r/survodutide — Week of 4/29 thread: Blinded trial accounts; assignments and identities unverified. Steps are trial-origin, not a community dose-finding study. Separate participants and endpoints must not be pooled.

Source context — DailyMed — ZEPBOUND prescribing information: Approved tirzepatide product only; does not validate investigational products, community interval changes or multi-agonist combinations.